However, rectal cancer (RC) accounts for only 12.7%-18.0% of index CRC in MMR gene variant carriers [1, 2, 4, 5], and there are very limited data on the risk of metachronous CRC and the site of occurrence after index RC surgery. This evidence concerns the gene MRC1 and colorectal carcinoma.